×
Agenda will be updated shortly. Stay tuned
×
- The views and opinions expressed in this presentation are those of the speaker, and do not reflect the official policy or position of Boehringer Ingelheim or any of its affiliates or subsidiaries
- Please click the timestamp to watch topic you are interested in.
- 00:00 Introduction
- “It’s Time to Act” – What is the urgency - 9:45 Glucose perspective - 19:20 Heart perspective - 38:07 Kidney perspective
- “Start Early” – Overcoming clinical inertia - 49:26 What are the words we should use to convey the sense of urgency? - 58:20 What are practical considerations before initiating SGLT2i? What to expect, what to monitor? - 1:07:55 How do you decide between SGLT2i or GLP1 RA? - 1:11:32 Is it safe to use SGLT2i in lean individuals?
- “Meet the Experts” – Live Q&A - 1:17:18 When would ACC/AHA HF guideline be updated? - 1:20:09 What should we do with patients with T2D without albuminuria, low eGFR without albuminuria and T2D? - 1:23:42 Could SGLT2i be beneficial on eyes as they are beneficial on heart and kidneys? - 1:26:46Is improving ejection fraction a goal of HF or reducing syndrome? - 1:31:56 DKA, Sick-day rules - 1:37:15 How low eGFR is safe to start and continue? - 1:40:50 Would you initiate eGFR for patients with HF and dialysis? Transplant? - 1:43:14 Would SGLT2i be beneficial to reduce new diabetes? - 1:48:02 UTI, GTI - 1:49:35 SGLT2i and GLP1-RA have any benefit in fatty liver disease? What is connection?
- 1:51:30 Take 5 summary
- PC-VN-102257
- The views and opinions expressed in this presentation are those of the speaker, and do not reflect the official policy or position of Boehringer Ingelheim or any of its affiliates or subsidiaries
- Please click the timestamp to watch topic you are interested in.
- 00:00 Introduction
- “An apple a day to keep diabetes at bay” – Going beyond glucose with SGLT2i - 5:56 Old strategies – and their benefits - 10:45 New medications – better chances - 20:09 New medications include a paradigm shift - 25:42 Take home message
- “An apple a day to keep diabetes at bay” – How do they work - 28:35 The mechanism for kidney protection
- “Making the evolution of diabetes management a revolution” – Panel discussion - 47:55Patient case introduction - 50:24 What should we have done with this patient? - 53:33 Risk factor management or Organ protection management? - 57:50 How to overcome inertia that SGLT2i would not work in patients eGFR below 45?
- “Meet the Experts” – Live Q&A - 59:19 Putting cost aside, would you consider SGLT2i as first line therapy? - 1:00:55 Which would you start GLP1 RA vs SGLT2i? - 1:03:48 Where does it lead metformin in management of T2D? - 1:05:58 How concerned are we about hypoglycemia with SGLT2i? - 1:09:01 What is the risk of DKA? - 1:12:20 Is there any intercurrent events disturb patients i.e. stroke, AKI? - 1:14:13 Is there a threshold of GFR drop? - 1:16:21 Are there any other ways to look at kidney damage? - 1:19:45 If a patient is already on metformin and DPP4i, would you stop that or add SGLT2i? - 1:21:13 Are there patients where you have to reduce anti-hypertensive medication? Or elderly or frail patients? - 1:23:10 How do you manage GTI? How frequently you see it? - 1:25:57 Do you have any advices in Asian patients with GLR and body weight levels in the use of SGLT2i? - 1:26:48 Is it something to consider in patients with ketogenic diet, impermanent fasting or fasting period?
- 1:28:52 Take 5 summary
- PC-VN-102419